UnitedHealth Group's i3 announces "Phase I" Business Expansion In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - After two years of plotting an entry into the Japanese healthcare market, i3 Japan LLC, a fully owned subsidiary of UnitedHealth Group, announced July 1 it would start offering its services actively in the clinical development and National Health Insurance areas as part of a "Phase I business expansion"
You may also be interested in...
Drug Makers Expedite Switch OTC Development, Sales After Japan Law Revision
TOKYO - Japanese drug makers are stepping up development and sales of switch OTC drugs with the hope of gaining market share, a continuing ripple effect from the recent amendment on OTC pharmaceuticals
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).